M.A. Bettaieb
A5022527637- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Neuroendocrine Tumor Research Advances
- Cancer, Hypoxia, and Metabolism
- Medical Imaging Techniques and Applications
- Neuroblastoma Research and Treatments
- Bone Tumor Diagnosis and Treatments
- Pituitary Gland Disorders and Treatments
- Kidney Stones and Urolithiasis Treatments
- Urological Disorders and Treatments
- Cancer, Lipids, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Pediatric Urology and Nephrology Studies
- Cancer Diagnosis and Treatment
Institut Gustave Roussy
2024
Hôpital Sahloul
2018-2020
<p>supplementary materials</p>
<div>AbstractPurpose:<p>This study aimed to explore metabolic tumor volume (MTV) as assessed by 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG–PET/CT) and understand its biological meaning in patients with non–small cell lung cancer (NSCLC) exposed immune checkpoint blockers (ICB).</p>Experimental Design:<p>In this study, advanced NSCLC a positive PET scan within 42 days of first-line treatment were enrolled 11 institutions across...
Abstract Purpose: This study aimed to explore metabolic tumor volume (tMTV) as assessed 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET/CT), and understand its biological meaning in patients with NSCLC exposed immune checkpoint blockers(ICBs). Experimental Design: In this study, advanced a positive PET scan within 42 days of first line treatment were enrolled 11 institutions across 4 countries. Total MTV was analyzed, 42% SUVmax threshold. Survival...